Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series.

Kristina Elizabeth Neergaard ClarkOliver CollasHelen LachmannAnimesh SinghJim BuckleySanjay Bhagani

Published in: Rheumatology advances in practice (2020)

Anakinra is safe to use i.v. in patients with COVID-19 and evidence of superadded bacterial infection. Although its utility has not been confirmed in a randomized trial, current research in the COVID-19 pandemic aims to establish the utility of immunosuppression, including IL-1 blockade, on the outcomes of patients with moderate to severe disease. Our case series supports its use in patients with severe, life-threatening COVID-19 and evidence of hyperinflammation.

Keyphrases

coronavirus disease
sars cov
early onset
high dose
low dose
high intensity
type diabetes
metabolic syndrome
adipose tissue
weight loss